BioSpace News Archive

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the following investor healthcare conferences: Citi’s 16th Annual BioPharma Conference.

Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conference

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS).

Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced today that it has closed on its Series A financing led by a non-disclosed major strategic investor along with a significant investment from ShangBay Capital, an early stage medical device investor as well as other investors including Mayo Clinic.

OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23 r d Annual Global Investment Conference. The conference is being held virtually on September 13 – 15, 2021.